Cantor Fitzgerald analyst Brandon Folkes maintained a Buy rating on Emergent Biosolutions (EBS) today and set a price target of $75. The company’s shares opened today at $55.92.
Folkes wrote:
“As investors appreciate the durability and revenue potential of Emergent’s portfolio, we expect upward earnings revisions and multiple expansion to drive the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $75. The Disclosure Section may be found on pages 4 – 6.Valuation We use a blend of DCF and EV/EBITDA to get to our PT of $75.”
According to TipRanks.com, Folkes is a 3-star analyst with an average return of 1.3% and a 40.4% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Emergent Biosolutions with a $69.50 average price target.
See today’s analyst top recommended stocks >>
Based on Emergent Biosolutions’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $3.4 million. In comparison, last year the company had a net profit of $33.94 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats.
